Q1 EPS Estimate for Agios Pharmaceuticals Reduced by Analyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Analysts at Zacks Research decreased their Q1 2025 earnings estimates for Agios Pharmaceuticals in a report issued on Wednesday, December 11th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of ($1.64) for the quarter, down from their prior estimate of ($1.63). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($0.39) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.72) EPS, FY2025 earnings at ($6.77) EPS, Q1 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.41) EPS and FY2026 earnings at ($5.70) EPS.

A number of other equities research analysts have also recently commented on the stock. Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Raymond James reaffirmed an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Scotiabank lifted their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Finally, StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Stock Down 1.7 %

AGIO opened at $41.96 on Monday. Agios Pharmaceuticals has a twelve month low of $20.96 and a twelve month high of $62.58. The company’s 50-day moving average price is $50.09 and its two-hundred day moving average price is $46.84. The stock has a market cap of $2.39 billion, a price-to-earnings ratio of 3.69 and a beta of 0.80.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 4.93% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new stake in Agios Pharmaceuticals during the second quarter valued at $37,000. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Agios Pharmaceuticals by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the last quarter. CWM LLC grew its holdings in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals in the third quarter worth approximately $146,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.